Nycomed acquisition by Takeda would boost global footprint
This article was originally published in Scrip
Executive Summary
While neither Takeda Pharmaceutical nor Nycomed have confirmed that they might be engaged in takeover talks, the continued strength of the Japanese Yen in the global economy, fast-approaching generic pressures and a strong strategic rationale all contribute to the validity of this rumored deal. And at a price mooted at between $10bn and $12bn, such a transaction would be the largest acquisition in Takeda's history, surpassing its $8.8 billion purchase of Millennium.